Cartesian Therapeutics, Inc. — Director's Dealing 2016

Jun 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-06-27

Reporting Person: Flagship Ventures Fund 2007, L.P. (10% Owner)
Reporting Person: Flagship Ventures 2007 General Partner LLC (10% Owner)
Reporting Person: AFEYAN NOUBAR (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-27	Common Stock	C	318752	—	Acquired	349867	Indirect
2016-06-27	Common Stock	C	631458	—	Acquired	981325	Indirect
2016-06-27	Common Stock	C	235042	—	Acquired	1216367	Indirect
2016-06-27	Common Stock	C	241718	—	Acquired	1458085	Indirect
2016-06-27	Common Stock	C	193777	—	Acquired	1651862	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-27	Series A Convertible Preferred Stock	$	C	318752	Disposed		Common Stock (318752)	Indirect
2016-06-27	Series B Convertible Preferred Stock	$	C	631458	Disposed		Common Stock (631458)	Indirect
2016-06-27	Series C Convertible Preferred Stock	$	C	235042	Disposed		Common Stock (235042)	Indirect
2016-06-27	Series D Convertible Preferred Stock	$	C	241718	Disposed		Common Stock (241718)	Indirect
2016-06-27	Series E Convertible Preferred Stock	$	C	125008	Disposed		Common Stock (193777)	Indirect

Footnotes

F1: Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F2: The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock automatically converted into common stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F3: The Series E Convertible Preferred Stock is convertible at any time, at the holder's election and has no expiration date. The Series E Convertible Preferred Stock automatically converted into common stock on an approximately 1-for-1.550115 basis upon the closing of the Issuer's initial public offering.